2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|November 1, 2019
SeraNovo Signs License Agreement with Carna Biosciences
Author(s)Pharmaceutical Technology Editors
Start-up company, SeraNovo, has revealed that it has signed a license agreement with Carna Biosciences to expand the existing collaboration and jointly develop an oral formulation of Carna’s kinase inhibitor with increase bioavailability.
Advertisement
Start-up company, SeraNovo, has revealed that it has signed a license agreement with Carna Biosciences to expand the existing collaboration and jointly develop an oral formulation of Carna’s kinase inhibitor with increase bioavailability.
The terms of the agreement, which were announced in an Oct. 30, 2019 press release, will see SeraNovo formulate one of Carna’s drugs using its proprietary Deep Eutectic Solvent (DES) formulation platform to improve bioavailability. It is anticipated that the final formulation will include an optimized combination of a DES along with one or more polymeric precipitation inhibitors as well as Carna’s kinase inhibitor.
“We are very excited that we have set up this important partnership with Carna Biosciences. We are confident this is just the first step in a long and fruitful partnership with an industry leader,” said Niall Hodgins, chief executive officer of SeraNovo in the press release. “As a start-up company, this partnership represents excellent validation for our breakthrough formulation technology.”
Source:
Advertisement
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Advertisement
Advertisement